Minor
PRESERVE-004 · ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Study completion pushed from Aug 30, 2026 to Aug 30, 2027
OncoC4, Inc.Phase 2 NCT05446298 Registry history of NCT05446298 on ClinicalTrials.gov (opens the registry)